PT  - JOURNAL ARTICLE
AU  - Ikenaka, Kensuke
AU  - Maeda, Yasuhiro
AU  - Hotta, Yuji
AU  - Nagano, Seiichi
AU  - Kakuda, Keita
AU  - Tatebe, Harutsugu
AU  - Atsuta, Naoki
AU  - Ito, Daisuke
AU  - Aguirre, Cesar
AU  - Kimura, Yasuyoshi
AU  - Baba, Kousuke
AU  - Katsuno, Masahisa
AU  - Tokuda, Takahiko
AU  - Kimura, Kazunori
AU  - Sobue, Gen
AU  - Mochizuki, Hideki
TI  - Serum asymmetric dimethyl arginine level correlates with the progression and prognosis of amyotrophic lateral sclerosis
AID  - 10.1101/2021.07.01.21259228
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.01.21259228
4099  - http://medrxiv.org/content/early/2021/07/06/2021.07.01.21259228.short
4100  - http://medrxiv.org/content/early/2021/07/06/2021.07.01.21259228.full
AB  - Objective To investigate the association between serum asymmetric dimethylarginine (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis (ALS), and to compare cerebrospinal fluid (CSF) and serum ADMA levels with other biomarkers of ALS.Methods Serum ADMA levels of patients with sporadic ALS (n = 68) and disease control patients (n = 54) were measured using liquid chromatography-tandem mass spectrometry. Serum samples were obtained at the time of patient registration for diagnosis. Correlations of ADMA level and other markers (nitric oxide [NO] and neurofilament light chain [NFL] levels) were analyzed. Changes in the ALS Functional Rating Scale–Revised (ALSFRS-R) score from the onset of disease (ALSFRS-R preslope) was used to assess disease progression. Survival was evaluated using the Cox proportional hazards model and Kaplan–Meier analysis.Results The concentration of ADMA in CSF was substantially higher in patients with ALS than in disease controls. Serum ADMA level correlated with CSF ADMA level (r = 0.591, p < 0.0001), and was independently associated with the ALSFRS-R preslope (r = 0.505. p < 0.0001). Patients with higher serum ADMA levels had less favorable prognoses. CSF ADMA level significantly correlated with CSF NfL level (r = 0.456, p = 0.0002) but not with NO level (r = 0.194, p = 0.219).Conclusion ADMA level is an independent biomarker of ALS disease progression and prognosis, and reflects the degree of motor neuron degeneration. The increased ADMA level in ALS patients was not associated with the inhibition of NO production.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Kanae Foundation for the Promotion of Medical Science and Japan Agency for Medical Research and Development (grant no. JP21wm0425013).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects endorsed by the Japanese government. The Ethics Committee of Osaka University Graduate School of Medicine approved the study (Approval number; 19089-3). All the patients, including disease controls, were informed about this study and written consent have been obtained.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnot applicableAbbreviationsADLactivities of daily livingADMAasymmetric dimethyl arginineALSamyotrophic lateral sclerosisALSFRS-RALS Functional Rating Scale-RevisedCIconfidence intervalCKcreatinine kinaseCSFcerebrospinal fluidFVCforced vital capacityHRhazard ratioMMTmanual muscle testingNfLneurofilament light chainTPPVtracheostomy positive pressure ventilation